

## PRODUCT INFORMATION

<b>Common Name</b>	MDX-1333, MEDI-546, anifrolumab-fnia
<b>Conjugate</b>	PE-conjugated
<b>Synonyms</b>	IFN-R-1;CRF2-1;IFNAR
<b>Applications</b>	Flow Cyt
<b>Recommended Dilutions</b>	Flow Cyt 1:400
<b>Formulation &amp; Reconstitution</b>	Liquid PBS with 0.05% Proclin300, 1% BSA
<b>Host Species</b>	Homo sapiens
<b>IgG type</b>	Human IgG1 - kappa
<b>Reactivity</b>	Human
<b>Target</b>	IFNAR1
<b>Uniprot ID</b>	P17181
<b>Description</b>	PE-conjugated Anti-IFNAR1(anifrolumab biosimilar) mAb
<b>Delivery</b>	In Stock
<b>Storage&amp;Shipping</b>	Store at 2°C-8°C for 6 months
<b>Background</b>	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
<b>Usage</b>	Research use only






Figure 1. Flow cytometry analysis with 100  $\mu$ l/test (1:400) PE-conjugated PE-conjugated Anti-IFNAR1(anifrolumab biosimilar) mAb (BME100117P) on HEK293 cells transfected with Human IFNAR1 protein (Blue histogram) or HEK293 transfected with irrelevant protein (Red histogram).

